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The association between chromosomal radiosensitivity and genetic predisposition to head and neck cancer was investigated in this
study. In all, 101 head and neck cancer patients and 75 healthy control individuals were included in the study. The G2 assay was used
to measure chromosomal radiosensitivity. The results demonstrated that head and neck cancer patients had a statistically higher
number of radiation-induced chromatid breaks than controls, with mean values of 1.23 and 1.10 breaks per cell, respectively
(Po0.001). Using the 90th percentile of the G2 scores of the healthy individuals as a cutoff value for chromosomal radiosensitivity,
26% of the cancer patients were radiosensitive compared with 9% of the healthy controls (P¼0.008). The mean number of
radiation-induced chromatid breaks and the proportion of radiosensitive individuals were highest for oral cavity cancer patients (1.26
breaks per cell, 38%) and pharynx cancer patients (1.27 breaks per cell, 35%). The difference between patients and controls was most
pronounced in the lower age group (p50 years, 1.32 breaks per cell, 38%) and in the non- and light smoking patient group (p10
pack-years, 1.28 breaks per cell, 46%). In conclusion, enhanced chromosomal radiosensitivity is a marker of genetic predisposition to
head and neck cancer, and the genetic contribution is highest for oral cavity and pharynx cancer patients and for early onset and
non- and light smoking patients.
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Enhanced chromosomal radiosensitivity has been observed in a
large number of patients with cancer-prone genetic diseases such
as ataxia–telangiectasia and Nijmegen breakage syndrome (Gatti,
2001). Several studies have shown that enhanced chromosomal
radiosensitivity is also present in a significant proportion of cancer
patients (Scott et al, 1994, 1998, 1999; Parshad et al, 1996; Patel
et al, 1997; Terzoudi et al, 2000; Baria et al, 2001, 2002; Buchholz
and Wu, 2001; Papworth et al, 2001; Riches et al, 2001; Baeyens
et al, 2002, 2005; Ban et al, 2004; Howe et al, 2005; Kolusayin Ozar
and Orta, 2005; Mozdarani et al, 2005; Distel et al, 2006; Lisowska
et al, 2006; Varga et al, 2006). The majority of data have been
collected in studies considering breast cancer patients whose
lymphocytes were irradiated in the G2 phase of the cell cycle (Scott
et al, 1994, 1999; Parshad et al, 1996; Patel et al, 1997; Terzoudi
et al, 2000; Baria et al, 2001; Buchholz and Wu, 2001; Riches et al,
2001; Baeyens et al, 2002, 2005; Howe et al, 2005; Djuzenova et al,
2006; Docherty et al, 2007). In a high number of these studies, it
was found that approximately 40% of breast cancer patients show
an increased G2 chromosomal radiosensitivity (Scott et al, 1994,
1999; Baria et al, 2001; Buchholz and Wu, 2001; Riches et al, 2001;
Baeyens et al, 2002, 2005). As it was also shown that healthy first-
degree relatives of breast cancer patients have an enhanced G2
sensitivity (Parshad et al, 1996; Patel et al, 1997), it has been
suggested that this elevated in vitro radiosensitivity may
be a marker of low-penetrant cancer-predisposing genes
(Roberts et al, 1999).
There is also indirect evidence for the existence of low-penetrant
predisposing genetic factors for head and neck cancers (Sturgis
et al, 2004). Although tobacco and alcohol consumption play a
major role in the aetiology of head and neck squamous cell
carcinoma (HNSCC), several large family studies demonstrated a
three- to eightfold increased risk of HNSCC in first-degree relatives
of patients with HNSCC (Copper et al, 1995; Foulkes et al, 1995,
1996). Furthermore, only a fraction of frequently exposed
individuals develop HNSCC and up to 20% of all HNSCC patients
develop the disease without any exposure to the main risk factors
(Sturgis et al, 2004). Finally, data emerging from case–control
studies using several phenotypic and genotypic assays support the
hypothesis of genetic susceptibility for HNSCC (Sturgis and Wei,
2002). Until recently, most of the studies evaluating phenotypic
assays as possible marker for head and neck cancer susceptibility
focused on the analysis of chromosomal damage in lymphocytes
after mutagen exposure (Schantz and Hsu, 1989; Schantz et al,
1989; Bondy et al, 1993; Spitz et al, 1993; Cloos et al, 1996; Wang
et al, 1998; Wu et al, 1998; Zhu et al, 2002; Szekely et al, 2005;
Xiong et al, 2007). Studies analysing chromosomal damage after
in vitro irradiation are, however, limited and often comprise a low
number of patients (Terzoudi et al, 2000; Papworth et al, 2001; Ban
et al, 2004; Distel et al, 2006; Lisowska et al, 2006). Nevertheless,
both Terzoudi et al (2000) and Lisowska et al (2006) reported
enhanced chromosomal radiosensitivity in larynx cancer patients,
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sand Papworth et al (2001) observed increased chromosomal
radiosensitivity in young head and neck cancer patients.
In the present study, we investigated the association between
chromosomal radiosensitivity and genetic predisposition to head
and neck cancer using the G2 assay for peripheral blood
lymphocytes. An analysis of the data according to tumour
histology and tumour location was performed. In addition, the
influence of age of onset of the disease and the effect of smoking
habits on genetic predisposition was investigated.
MATERIALS AND METHODS
Population
The study population consisted of 101 head and neck cancer
patients recruited from the Radiation Oncology Department of the
Ghent University Hospital between January 2003 and October
2005. All patients were newly diagnosed, previously untreated and
histologically confirmed. The cases included 83 squamous cell
carcinomas (SCCs), 12 adenocarcinomas (ACs) and 6 other or
unknown carcinomas. A total of 13 patients had cancer of the oral
cavity, 37 patients suffered from pharyngeal cancer, 29 patients
had laryngeal cancer and 22 patients were diagnosed with sinus
cancer or cancer of unknown primary. The population consisted of
84 men and 17 women, and the mean age of the patients at the time
of treatment was 60 years (range: 33–91 years) (Table 1).
From each patient in the study, a heparinised blood sample was
taken before therapy and the G2 assay was performed on the
sampling day. At the same time, parallel cultures from healthy
individuals were started. The samples of the healthy control
individuals were collected at the Occupational Medicine Depart-
ment of the Ghent University Hospital. Details of the control
population are described in Table 1. The study was approved by
the Ethical Committee of the Ghent University Hospital. All study
participants signed an informed consent form and completed a
detailed questionnaire on smoking and drinking habits. Smoking
was quantified by the degree of tobacco consumption categorised
as pack-years (1 pack-year¼20 cigarettes per day for 1 year).
Alcohol exposure was determined by the number of alcoholic
drinks per week. For four patients and two control individuals, no
smoking and drinking data were available.
G2 assay
The G2 assay procedure of the Paterson Institute (Manchester)
was applied with some minor changes. Briefly, heparinised blood
was kept at room temperature before culturing within 4h after
prelevation. To a tissue culture flask (25cm
2), 0.5ml blood
was added to 4.5ml complete RPMI-1640 culture medium
supplemented with 10% fetal calf serum (Invitrogen, Merelbeke,
Belgium), 1% L-glutamine, 50Uml
 1 penicillin and 50mgml
 1
streptomycin. The lymphocytes were stimulated to divide with 1%
phytohemagglutinin (Invitrogen). Per donor two cultures were
started, one served as control, the other for in vitro irradiation.
After 70h incubation in a CO2 incubator at 371C, the cultures were
irradiated with a dose of 0.4Gy
60Co rays at 371C. At 30min post
irradiation, 75ml colcemid (final concentration 0.15mgml
 1;
Sigma-Aldrich, Bornem, Belgium) was added to block the cells at
metaphase, and at 90min post irradiation the cultures were
arrested by putting them on ice for 5min. The cells were harvested
by centrifugation of the samples, and the cell pellets were
resuspended in 5ml of 0.075 M KCl for 15min on ice. After the
hypotonic shock, the cells were fixed three times in 5ml cold
methanol/acetic acid (3:1). Finally, cells were dropped on clean
slides and stained with 4% Azur B SCN solution (Polylab,
Merksem, Belgium). Fifty well-spread metaphases were analysed
by two independent scorers on coded slides for the appearance of
chromatid breaks. All types of single chromatid breaks where a
clear discontinuity was present were scored (Bryant et al, 2002).
Table 1 Characteristics of the study population
Controls (%) Patients (%)
Characteristic (n¼75) (n¼101)
Sex
Male 41 (54.7) 84 (83.2)
Female 34 (45.3) 17 (16.8)
Mean age ±s.d. 45±13.7 60±10.0
Anatomic tumour location
Oral cavity — 13 (12.9)
Pharynx — 37 (36.6)
Larynx — 29 (28.7)
Other and unknown — 22 (21.8)
Tumour histology
Squamous cell carcinoma (SCC) — 83 (82.2)
Adenocarcinoma — 12 (11.9)
Other and unknown — 6 (5.9)
Mean pack-years ±s.d. 7±11.6 33±21.5
Mean drinks per week ±s.d. 6±5.4 28±27.9
Table 2 Overview of the G2 data
Head and neck cancer patients
Tumour histology Tumour location
Controls All SCC AC Oral cavity Pharynx Larynx
Population size 75 101 83 12 13 37 29
Mean±s.d.
a 1.10±0.18 1.23±0.20 1.23±0.20 1.21±0.24 1.26±0.23 1.27±0.24 1.18±0.14
Range
a 0.64–1.54 0.75–1.81 0.75–1.81 0.90–1.76 0.94–1.76 0.75–1.81 0.96–1.43
P-value
b o0.001 o0.001 0.166 0.021 o0.001 0.024
Cut-off value
c 1.33
% 4cut off value 9 26 28 25 38 35 17
P-value
d 0.008 0.005 0.261 0.018 0.002 0.419
OR (95% CI) Ref
e 3.37 (1.37–8.26) 3.72 (1.49–9.29) 3.24 (0.71–14.82) 6.07 (1.56–23.69) 5.26 (1.88–14.74) 2.02 (0.59–6.98)
P-value
f 0.008 0.005 0.130 0.009 0.002 0.265
AD, adenocarcinoma; CI, confidence interval; OR, odds ratio; SCC, squamous cell carcinoma.






eRef, reference: control individuals with p1.33 breaks per cell were used as reference.
fLogistic regression.
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Statistical analysis was performed by SPSS 12.0 software (SPSS
Inc., Chicago, IL, USA). For the comparison of the mean G2 scores
between different groups, the Mann–Whitney test was applied.
Differences in the proportions of radiosensitive individuals in the
different populations were compared using the w
2 test. Uncondi-
tional logistic regression analyses were performed to calculate ORs
(odds ratios) and 95% CIs (95% confidence intervals). Pearson
correlation coefficients were used to study the correlation between
aberration frequencies, age, smoking and drinking.
RESULTS
Chromosomal radiosensitivity G2 data were collected for 75
healthy individuals and 101 head and neck cancer patients. For
each sample, the spontaneous yield of chromatid breaks was
subtracted from the yield in irradiated cells to obtain the radiation-
induced aberration yield.
The results for the head and neck cancer patients and for the
healthy individuals are summarised in Table 2 and graphically
displayed in Figures 1 and 2. The average yield of radiation-
induced chromatid breaks per cell was 1.10 for healthy individuals
and 1.23 for all head and neck cancer patients (Po0.001).
According to tumour histology, patients with SCC and AC were
considered. Patients with SCC had 1.23 breaks per cell (Po0.001),
whereas those with AC had 1.21 breaks per cell (P¼0.166). Using
the 90th percentile of the G2 scores of the healthy individuals as a
cutoff value for chromosomal radiosensitivity (1.33 breaks per
cell), 26% of all cancer patients, 28% of SCC patients and 25% of
AC patients were radiosensitive compared with 9% of the healthy
individuals (P¼0.008, 0.005 and 0.261, respectively). This
corresponds, respectively, to ORs with respect to cancer incidence
of 3.37 (P¼0.008), 3.72 (P¼0.005) and 3.24 (P¼0.130) for
individuals with G2 scores exceeding 1.33 breaks per cell (Table 2).
According to anatomic tumour location, three patients subgroups
were considered: (1) patients with oral cavity cancer, (2) patients
with pharyngeal cancer and (3) patients with laryngeal cancer.
Patients from each subgroup had significantly more chromatid
breaks per cell compared with the individuals from the healthy
control group (P¼0.021, o0.001 and 0.024, respectively). On the
basis of the 90th percentile cutoff value, 38% of the oral cavity
cancer patients, 35% of the pharynx cancer patients and 17% of the
larynx cancer patients were radiosensitive (P¼0.018, 0.002 and
0.419, respectively). Consequently, individuals with increased
chromosomal radiosensitivity had a six-, five- or two-fold
increased risk to develop oral cavity cancer, pharynx cancer or
larynx cancer (P¼0.009, 0.002 or 0.265), respectively.
For further analyses, the patients were stratified according to
age, smoking habits and alcohol intake, and chromosomal
radiosensitivity was evaluated in the subsequent subgroups. The
results of these analyses are presented in Table 3. No significant
effect of age was seen on radiation-induced aberrations in
individual patients and controls (P40.100), but stratified analysis
showed the highest mean G2 scores for the youngest patients.
Patients with ages p50, between 450 and p70, and 470 years
had 1.32, 1.22 and 1.18 breaks per cell, respectively. Except for the
oldest patient group (P¼0.269), these results were significantly
different from the control population (P¼0.004 and o0.001,
respectively). Using the cutoff value of the healthy control group,
38% of the patients with age p50 years (P¼0.009) were
radiosensitive. Consequently, radiosensitive individuals p50 years
had a six-fold increased risk for developing head and neck cancer
(P¼0.007). There was also no correlation between smoking and
radiation-induced aberrations in patients and controls (P40.130).
Nevertheless, the highest mean G2 scores were found for non- and
light smoking patients. Patients with p10, between 410 and p25,
and 425 pack-years had 1.28, 1.22 and 1.21 breaks per cell,
respectively. The results of all subgroups defined according to
smoking habits were statistically significant compared with the
control population (P¼0.006, 0.007 and 0.001, respectively). On
the basis of the cutoff value of the healthy control group, 46% of
the patients with p10 pack-years (P¼0.003) were radiosensitive.
Accordingly, an OR of 8.33 (P¼0.002) was found for non- and
light smoking individuals. A similar trend was not seen for alcohol
intake in the patient population, nor for any of the three
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Figure 1 Distribution of radiation-induced G2 chromatid breaks in
healthy individuals (n¼75), all head and neck cancer (n¼101), SCC
(n¼83) and AC patients (n¼12). The vertical line represents the 90th
percentile cutoff point.
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The association between G2 chromosomal radiosensitivity and
genetic predisposition to head and neck cancer was investigated in
the present study. Moreover, an analysis of the data according to
tumour histology and tumour location was performed, and the
influence of age of onset of the disease and the effect of smoking
habits on genetic predisposition were investigated.
Analysis of the data shows that head and neck cancer patients
have a significantly higher mean number of in vitro radiation-
induced chromatid breaks per cell than healthy individuals (1.23 vs
1.10 breaks per cell, Po0.001). The observed elevated chromoso-
mal radiosensitivity was independent of tumour histology and
tumour location. Patients with SCC and AC, as well as patients with
oral cavity, pharynx and larynx cancers, all showed an increased
mean number of radiation-induced chromosomal aberrations
compared with the control group. Except for the AC patients, all
results were statistically significant. With respect to laryngeal
cancer, these results are in agreement with the findings of Terzoudi
et al (2000) and Lisowska et al (2006), who both reported enhanced
chromosomal radiosensitivity in larynx cancer patients. This
increase was statistically significant in the latter study, but in the
study of Terzoudi et al (2000), the statistical significance was not
mentioned. In the study of Lisowska et al, a very different
experimental protocol was used compared with the one applied in
the present study. Although five times higher irradiation doses
were used (2 vs 0.4Gy in the present study), five times lower mean
G2 values were obtained for larynx cancer patients (0.22 vs 1.18
breaks per cells in the present study). This discrepancy is at least
partly due to the fact that in the study of Lisowska et al, chromatid
breaks were analysed in metaphase cells 4.5h post irradiation,
whereas in the present study chromatid breaks were analysed in
metaphase cells 1.5h post irradiation. An exponential decline of
chromatid breaks with time after irradiation has been demon-
strated in the past by our research group and supports the
observed differences in absolute chromatid break numbers in both
studies (Vral et al, 2002). Concerning various head and neck
cancer patients, Papworth et al (2001) reported a nonsignificant
increase in mean radiation-induced chromosomal aberrations in
these patients. Next to the positive association found between high
levels of radiation-induced chromatid breaks and increased risk
for head and neck cancer, several studies also reported a positive
association between high frequencies of chromatid breaks after
bleomycin or benzo[a]pyrene diol epoxide (BPDE) exposure and
elevated risk for head and neck cancer (Cloos et al, 1996; Wang
et al, 1998; Wu et al, 1998; Zhu et al, 2002; Szekely et al, 2005;
Xiong et al, 2007). As radiation as well as bleomycin and BPDE
cause DNA damage, both assays are linked to DNA repair capacity.
Consequently, the observed enhanced chromosomal radiosensiti-
vity in cancer patients indicates that suboptimal repair of DNA
damage contributes to the genetic susceptibility to head and neck
cancer. Alternatively, the observed enhanced chromosomal radio-
sensitivity may also result from a less efficient G2/M checkpoint, as
it has been shown that G2 checkpoint abrogation comprises repair
of chromosome damage and that defects in the G2/M checkpoint
are associated with increased cancer risk (Terzoudi et al, 2005; Wu
et al, 2005; Zheng et al, 2005).
Although in this study the mean number of radiation-induced
aberrations was significantly higher in the studied cancer
population compared with the healthy control population, an



















































































































0.73 0.83 0.93 1.03 1.13 1.23 1.33 1.43 1.53 1.63 1.73 1.83
0.73 0.83 0.93 1.03 1.13 1.23 1.33 1.43 1.53 1.63 1.73 1.83
0.73 0.83 0.93 1.03 1.13 1.23 1.33 1.43 1.53 1.63 1.73 1.83
0.73 0.83 0.93 1.03 1.13 1.23 1.33 1.43 1.53 1.63 1.73 1.83
0.73 0.83 0.93 1.03 1.13 1.23 1.33 1.43 1.53 1.63 1.73 1.83






















Figure 2 Distribution of radiation-induced G2 chromatid breaks in
healthy individuals (n¼75), all head and neck cancer (n¼101), oral cavity
cancer (n¼13), pharynx cancer (n¼37) and larynx cancer patients
(n¼29). The vertical line represents the 90th percentile cutoff point.
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sabove which an individual can be considered as radiosensitive, was
determined (Scott et al, 1999). With this value, the proportion of
radiosensitive individuals can be compared between different
populations. As in most studies, the 90th percentile of the normal
population was considered as cutoff point. Using this threshold for
chromosomal radiosensitivity, 26% of the head and neck cancer
patients were radiosensitive compared with 9% of the healthy
individuals (P¼0.008). A high proportion of radiosensitive cases
(31%) among various head and neck cancer patients have also
been reported by Papworth et al (2001). Subdividing our large
patient group according to anatomic location of the tumour
revealed that the high G2 scores were mainly attributable to the
oral cavity and pharyngeal cancer patients of which 38 and 35%,
respectively, were radiosensitive (P¼0.018 and 0.002). Of the
laryngeal cancer patients, in contrast, only 17% of the patients
were radiosensitive (P¼0.419). In the study of Lisowska et al
(2006), a higher and significant proportion of radiosensitive
individuals (40%) among larynx cancer patients was reported.
Because a very different experimental protocol is used by Lisowska
et al, compared with the present study, this could explain the
difference in the number of radiosensitive larynx cancer patients.
In this study, no correlation has been found between radiation-
induced aberration frequency and age, pack-years of smoking and
drinks per week in patients and controls. Concerning age, this has
also been published in other studies (Scott et al, 1999; Riches et al,
2001; Vral et al, 2007). For smoking and drinking exposure, no
data are available in the literature for their effect on the level of
radiation-induced aberrations. It has, however, been shown that
age, smoking and alcohol intake do not influence mutagen-
induced chromosomal aberrations (Cloos et al, 1996). Despite the
lack of correlation on individual level, grouped analysis showed
that patients p50 years and with p10 pack-years had the highest
mean number of chromatid breaks. On the basis of the 90th
percentile cutoff value, 38% of the patients aged 50 years or less
were radiosensitive (P¼0.009). Similar proportions of in vitro
radiosensitive young head and neck cancer patients have also been
reported by Papworth et al (2001) (38%, p45 years). Our patient
group included only five patients p45 years but 60% of them were
in vitro radiosensitive (P¼0.008). These results indicate that the
genetic contribution, as measured by in vitro radiosensitivity, to
head and neck cancer risk is higher for early onset cases. This
finding for head and neck cancer patients differs from that for
breast cancer patients in that no age dependence for G2 sensitivity
could be found in the latter group (Baeyens et al, 2005). As cancer
at young age is a hallmark of heredity, this indicates that
individuals at risk for early onset head and neck cancer possess
a higher number of low-penetrant predisposing genes or a number
of highly penetrant predisposing genes involved in DNA repair
pathways compared with late-onset head and neck cancer patients
and early onset breast cancer patients. Concerning tobacco
exposure, it was found that non- and light smoking patients had
the highest mean number of radiation-induced chromatid breaks.
This indicates the existence of a larger genetic predisposition in
non- and moderately tobacco-exposed individuals and supports
the possibility of important gene–environment interactions in the
development of head and neck cancer (Xiong et al, 2007).
In conclusion, this study supports the fact that chromosomal
radiosensitivity of lymphocytes is a marker of genetic predisposi-
tion to head and neck cancer. Analyses of different subgroups
revealed that the genetic contribution is highest for oral cavity and
pharynx cancer patients and is more pronounced for early onset
and non- and light smoking patients.
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